CMO Perspectives

Stay up to date on the latest clinical research and trends in Coronary Artery Disease diagnostic testing with our Chief Medical Officer, Dr. Campbell Rogers.

Featured Article

A better diagnostic pathway can have a direct impact on patient survival as better information enables better treatment.

SCCT 2023: Adapting and Advancing

  “It is not the strongest of the species that survives, nor the most intelligent. It is the one that is most adaptable to change.” – Charles Darwin Across healthcare today, clinicians have been handed a priority list so long as to border on the implausible.  Clinically, patient partnerships1 are needed to improve outcomes. Economically, better care must be delivered without waste2.  Societally, health equity3 is a continuous focus.  Technologically, advancements4 must be evaluated and, as appropriate, incorporated.  And all of this is required whilst the structures in which we work are rapidly transforming5, for better or worse.  Given the task at hand, even

Read More
37 precise thumb

Discovering PRECISE-ly what our patients need: Learnings from the randomized PRECISE trial

  All truths are easy to understand once they are discovered; the point is to discover them. – Galileo Galilei Discovery drives clinical research. Whether we are testing a potential breakthrough therapy or the impact of a long-standing care practice, the chance to chart a path toward better heart health is why substantial effort and resources are regularly invested in cardiovascular trials. The search for a better path is what motivated the PRECISE trial, presented at AHA 2022. This randomized trial delivered strong evidence that a diagnostic pathway centered on coronary CTA + FFRCT, which was recommended in the 2021 AHA/ACC Chest Pain

Read More

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.

Sign Up for HeartFlow Communications

Stay current on the latest CMO Perspectives, product updates, webinars and other breaking HeartFlow news.